The Neopentylamine Market size is projected to grow at a CAGR of 5.1% during the forecast period (2022-2027) and reach US$2.1 billion by 2027. The growth of the neopentylamine market is primarily driven by the growth of the pharmaceutical sector. Neopentylamine (also known as 1-amino-2, 2-dimethylpropane or 2,2-dimethylpropylamine) is a primary amine derivative of neopentane that is mainly used as a pharmaceutical intermediate or active pharmaceutical ingredients utilized during the production of pharmaceutical drugs and medicines. The anti-inflammatory properties of neopentylamine make it ideal for use in such pharmaceutical applications. The surging developments associated with the pharmaceutical sector across the world have led to considerable growth in the Neopentylamine market. 

Neopentylamine Market: The Pharmaceutical Segment Leads the Market

On the basis of the end-use industry, the Neopentylamine Market can be segmented into pharmaceutical and chemical industries. The pharmaceutical sector is evaluated to be the leading segment in the neopentylamine market in 2021. During the forecast period 2021-2027, the pharmaceutical segment is expected to grow at a CAGR of 5.6%. This can be attributed to various reasons such as the increasing pharmaceutical production across the world. Recent insights from Atradius state that global pharmaceutical production increased significantly by 13.6% in 2021 as compared to 2020. It further states that the United States accounted for 22% of the total global pharmaceutical production in 2021.

For More Queries About "Neopentylamine Market" @

Neopentylamine Market: Asia-Pacific Holds the Largest Share

On the basis of geography, the Neopentylamine Market can be segmented into North America, South America, Europe, APAC and EMEA. According to IndustryARC’s analysis, Asia-Pacific has emerged as the most dominant region in the market. In 2021, the Asia-Pacific region held around 35% share of the total revenue earned by the market, globally. Asia-Pacific countries including China and India are comparatively ahead in terms of the growth of the pharmaceutical sector. According to Oxford Economics, the pharmaceutical sector in China witnessed a YoY growth of 28% in 2021 as compared to 2020. Moreover, according to the India Brand Equity Foundation (IBEF), the domestic pharmaceutical sector in India was valued at US$42 billion in 2021 and it is projected to increase up to US$65 billion by 2024 and US$30 billion by 2030.

The Neopentylamine Market would also witness significant growth in the North American region. The U.S. and Canada are emerging as competitive countries in the neopentylamine market. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the USA and Canada accounted for 49.1% of the total pharmaceutical market in 2021.

Neopentylamine Market: Competitive Landscape

Key companies holding major shares in the Neopentylamine Market are TCI Chemicals, Alfa Chemistry, 3B Scientific Corporation, Apollo Scientific, City Chemicals, VWR International, ChongQing Purel Bio-Pharmaceutical Technology, J & K Scientific, Beijing Ouhe Technology and Shanghai Longsheng Chemical.

To request for a quote, provide your details in the below link:

Media Contact:
Mr. Venkat Reddy
Sales Manager
Contact Sales: +1-970-236-3677

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.